Efficacy and safety of APSAC in the treatment of acute myocardial infarction.
A prospective, open, multicentre post-marketing surveillance on the efficacy and safety of intravenous APSAC in the treatment of acute myocardial infarction was performed in 2436 patients. Reperfusion suggested by non-invasive parameters was achieved in 77.3% of patients. In-hospital mortality was low (7.1%). After exclusion from analysis of patients greater than 70 years of age and those reported to be in cardiogenic shock, mortality rate was 2.9%. More importantly, non-invasive evidence for successful thrombolysis resulted in a significantly lower mortality (3.3%) compared with patients without evidence of successful reperfusion (17.2%). The incidence of serious adverse events was low (132 in 2436 patients, 8/2436 = 0.3% fatal). The data from this post-marketing surveillance conducted under every-day clinical conditions confirm the efficacy and safety of APSAC as a thrombolytic agent in acute myocardial infarction, as demonstrated previously in controlled clinical trials.